Physician profile
Christopher M Speidel
NPI 1427037936
$2,919.27
in general payments reported to CMS, 2019-2025
32 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $175 · 2021: $25.11 · 2022: $75.05 · 2023: $478 · 2024: $1,010 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $686.09 | 2019-2025 | |
| Amgen INC. | $451.75 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $224.02 | 2019-2024 | Brilinta, Wainua |
| Janssen Pharmaceuticals, INC | $171.93 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $151.70 | 2019-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $117.14 | 2023-2025 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.40 | 2019-2025 | Lifevest |
| Pfizer INC. | $96.27 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.98 | 2019-2024 | Jardiance |
| Siemens Medical Solutions USA, INC. | $84.93 | 2024-2025 | Acuson Origin Diagnostic Ultrasound System |
| Edwards Lifesciences Corporation | $73.15 | 2022-2024 | Pascal |
| Regeneron Healthcare Solutions, INC. | $66.35 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $54.38 | 2019-2024 | |
| Inari Medical, INC. | $52.12 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $47.47 | 2024-2025 | Impella |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $45.50 | 2024 | Arcalyst |
| Heartflow, INC. | $44.87 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $40.25 | 2023-2024 | Verquvo |
| Scpharmaceuticals INC. | $39.88 | 2023-2024 | |
| Abbott Laboratories | $38.55 | 2021-2022 | |
| Chiesi USA, INC. | $33.52 | 2022-2024 | Kengreal |
| Medtronic, INC. | $31.09 | 2023 | Linq II |
| Kiniksa Pharmaceuticals, LTD. | $28.00 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $19.61 | 2019 | |
| Boston Scientific Corporation | $18.49 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.06 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $17.46 | 2024 | Nexletol |
| Cvrx, INC. | $17.10 | 2024 | Barostim Neo System |
| Cardiva Medical, INC. | $15.40 | 2022 | |
| Medtronic Vascular, INC. | $14.51 | 2020 | |
| Cook Medical LLC | $12.91 | 2023 | Cook Celect |
| Philips North America LLC | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Speidel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.